Key Financial Figures - Consolidated (Q2 FY2027)

  • Revenue from Operations: ₹892.37 Crores (Sale of Products: ₹889.50 Cr, Other Operating Income: ₹2.87 Cr)
  • Other Income: ₹3.20 Crores
  • Total Income: ₹895.57 Crores
  • Total Expenses: ₹702.86 Crores
  • Profit before share of profit from joint venture & tax: ₹192.71 Crores
  • Share of loss from investment in joint venture: ₹0.90 Crores
  • Profit before exceptional item and tax: ₹191.81 Crores
  • Exceptional Items: ₹35.90 Crores (Settlement with customers for products launched at risk)
  • Profit before tax: ₹155.91 Crores
  • Tax Expense: Net credit of ₹31.23 Crores (Current tax: ₹64.78 Cr credit, Deferred tax: ₹33.55 Cr charge)
  • Net Profit for the period: ₹187.14 Crores
  • Attributable to owners: ₹183.82 Crores
  • Attributable to non-controlling interest: ₹3.32 Crores
  • Earnings Per Share (Basic): ₹13.26
  • Earnings Per Share (Diluted): ₹13.25

Key Financial Figures - Consolidated (H1 FY2027)

  • Revenue from Operations: ₹1,765.62 Crores
  • Net Profit for the period: ₹330.46 Crores
  • Attributable to owners: ₹326.21 Crores
  • Attributable to non-controlling interest: ₹4.25 Crores
  • Earnings Per Share (Basic): ₹23.54
  • Earnings Per Share (Diluted): ₹23.53

Key Financial Figures - Standalone (Q2 FY2027)

  • Revenue from Operations: ₹482.24 Crores
  • Net Profit for the period: ₹129.15 Crores
  • Earnings Per Share (Basic): ₹9.32
  • Earnings Per Share (Diluted): ₹9.31

Key Financial Figures - Standalone (H1 FY2027)

  • Revenue from Operations: ₹926.24 Crores
  • Net Profit for the period: ₹177.46 Crores
  • Earnings Per Share (Basic): ₹12.81
  • Earnings Per Share (Diluted): ₹12.80

Consolidated Balance Sheet (as at September 30, 2026)

  • Total Assets: ₹7,581.20 Crores (Non-current: ₹5,780.34 Cr, Current: ₹1,800.86 Cr)
  • Total Equity: ₹4,141.58 Crores (Equity share capital: ₹13.87 Cr, Other equity: ₹4,130.47 Cr, Non-controlling interest: -₹2.76 Cr)
  • Total Liabilities: ₹3,439.62 Crores (Non-current: ₹738.41 Cr, Current: ₹2,681.14 Cr)
  • Borrowings: ₹2,381.80 Crores (Non-current: ₹427.46 Cr, Current: ₹1,954.34 Cr)

Standalone Balance Sheet (as at September 30, 2026)

  • Total Assets: ₹5,747.28 Crores
  • Total Equity: ₹3,288.42 Crores
  • Total Liabilities: ₹2,458.86 Crores
  • Borrowings: ₹1,952.83 Crores

Cash Flow Highlights - Consolidated (H1 FY2027)

  • Net cash from operating activities: ₹637.13 Crores
  • Net cash used in investing activities: ₹284.66 Crores
  • Net cash used in financing activities: ₹169.12 Crores
  • Net increase in cash: ₹183.35 Crores
  • Cash and cash equivalents at end: ₹238.09 Crores

Cash Flow Highlights - Standalone (H1 FY2027)

  • Net cash from operating activities: -₹35.33 Crores
  • Net cash from investing activities: ₹97.57 Crores
  • Net cash used in financing activities: ₹84.23 Crores
  • Net decrease in cash: ₹21.99 Crores
  • Cash and cash equivalents at end: ₹3.19 Crores

Key Ratios - Consolidated

  • Debt-Equity Ratio: 0.59 times (Q2 FY2027)
  • Debt Service Coverage Ratio: 3.12 times (Q2 FY2027)
  • Interest Service Coverage Ratio: 5.15 times (Q2 FY2027)
  • Current Ratio: 0.67 times (Q2 FY2027)
  • Operating Margin: 26.80% (Q2 FY2027)
  • Net Profit Margin: 20.97% (Q2 FY2027)

Key Ratios - Standalone

  • Debt-Equity Ratio: 0.60 times (Q2 FY2027)
  • Interest Service Coverage Ratio: 3.84 times (Q2 FY2027)
  • Current Ratio: 0.53 times (Q2 FY2027)
  • Operating Margin: 33.48% (Q2 FY2027)
  • Net Profit Margin: 26.78% (Q2 FY2027)

Significant Events and Notes

1. Exceptional Items: A settlement with customers for supply of products launched at risk in earlier periods resulted in a write-down of ₹35.90 Crores (net of collections and past provisions).

2. Scheme of Arrangement: The Scheme involving Aprica Healthcare Limited (AHL), Eris Oaknet Healthcare Private Limited (EOHPL), and Eris Therapeutics Limited (ETL) was approved by NCLT on September 24, 2026, with an appointed date of April 1, 2025. The Scheme became effective on October 22, 2026. This allowed:

  • Business losses of EOHPL to be set off against ETL's profits
  • Amortisation of Brand assets became tax deductible for ETL
  • Resulted in a current tax credit of ₹96 Crores and deferred tax charge of ₹31 Crores in consolidated results
  • Goodwill adjusted for deferred tax liabilities on brand assets amounting to ₹220 Crores as of the appointed date

3. Employee Stock Options: The company allotted 195,682 equity shares of ₹1 each under the Employee Stock Option Scheme 2021 during H1 FY2027.

4. Business Acquisition: Completed acquisition of Branded Probiotics Business from Velbiom Probiotics Private Limited for ₹50 Crores on a slump sale basis on March 31, 2026. Purchase price allocation is in progress.

5. Labour Code Impact: The implementation of new Labour Codes effective November 21, 2025, increased gratuity and leave liabilities due to changes in the definition of "wages". This resulted in an exceptional item of ₹17.24 Crores in FY2026 consolidated results and ₹14.67 Crores in FY2026 standalone results.

6. Auditor's Review: Walker Chandiok & Co LLP issued an unmodified review report on both standalone and consolidated financial results. The review covered the holding company and most subsidiaries, except for 5 subsidiaries and 1 joint venture whose financials were reviewed by other auditors.

Entities Included in Consolidated Results

  • Holding Company: Eris Lifesciences Limited
  • Subsidiaries: Eris Therapeutics Limited, Eris Oaknet Healthcare Private Limited, Eris Healthcare Private Limited, Eris M. J. Biopharm Private Limited, Eris Pharmaceuticals Limited, Eris Bionxt Private Limited, Swiss Parenterals Limited
  • Joint Venture: Levim Lifetech Private Limited